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Background: Chronic hepatitis C (CHC) and its treatment are associated with a variety of patient-reported
symptoms and impacts. Some CHC symptoms and impacts may be difficult to evaluate through objective clinical
testing, and more easily measured through patient self-report. This literature review identified concepts raised by
CHC patients related to symptoms, impacts, and treatment effects, and evaluated integration of these concepts
within patient-reported outcome (PRO) measures. The goal of this work was to provide recommendations for
incorporation of PRO measurement of concepts that are relevant to the CHC experience into CHC clinical trial
design.
Methods: A three-tiered literature search was conducted. This included searches on concepts of importance, PRO
measures used in clinical trials, and existing PRO measures. The PRO Concept Search focused on reviewing issues
raised by CHC patients about CHC symptoms, disease impact, and treatment effects. The CHC Trials with PRO
Endpoints Search reviewed clinical trials with PRO endpoints to assess differences between treatments over time.
The PRO Measure Search reviewed existing PRO measures associated with the concepts of interest.
Results: This multi-tiered approach identified five key concepts of interest: depression/anxiety, fatigue, flu-like
symptoms, cognitive function, insomnia. Comparing these five concepts of interest to the PRO measures in
published CHC clinical trials showed that, while treatment of CHC may decrease health-related quality of life in a
number of mental and physical domains, the PRO measures that were utilized in published clinical trials
inadequately covered the concepts of interest. Further review of 18 existing PRO measures of the concepts of
interest showed only four of the 18 were validated in CHC populations.
Conclusions: This review identified several gaps in the literature regarding assessment of symptoms and outcomes
reported as important by CHC patients. Further research is needed to ensure that CHC clinical trials evaluate
concepts that are important to patients and include measures that have evidence supporting content validity,
reliability, construct validity, and responsiveness.
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Hepatitis C virus (HCV) is a worldwide public health
concern that affects between 170 and 200 million
people. Approximately 60% to 80% of patients with acute
hepatitis C viral infection eventually develop chronic
hepatitis C (CHC) [1,2]. Individuals with CHC may
experience symptoms including nausea, fatigue, mus-
culoskeletal and abdominal pain, and headaches [3].* Correspondence: leah.kleinman@unitedbiosource.com
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reproduction in any medium, provided the orNeuropsychiatric symptoms such as depression, fatigue,
irritability, and malaise are reported by patients with
both acute and chronic hepatitis infection, with depres-
sion being the most frequently reported [4]. These
symptoms are bothersome to patients and often result in
reduced health-related quality of life (HRQL) [5,6].
The current standard of care (SOC) for treating CHC
patients with chronic infection is a regimen of interferon
alpha (IFN-α) and ribavirin (RBV). This combination has
been found to result in the highest sustained response
rates in clinical trials [7-9]. Although treatments demon-
strate acceptable efficacy, concerns about the severity ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rates of treatment noncompliance and apprehension
about starting treatment bolster these concerns [10].
Treatment with IFN-α and RBV can cause many severe
symptoms including physical fatigue, flu-like symptoms,
hair loss, gastrointestinal (GI) symptoms, headache, and
neuropsychological symptoms including mental fatigue,
concentration difficulties, depression, and irritability [1].
These symptoms in turn impact HRQL and patients’
ability to perform everyday activities [3].
CHC symptoms and treatment effects are difficult to
evaluate through objective clinical testing, although they
can be measured through patient self-report; that is,
patient-reported outcome (PRO) measures. The use of a
PRO measure provides insight into the patient perspec-
tive on the impact of disease and treatment [11]. PRO
measures must have content validity, meaning there
must be clear evidence demonstrating that the patients’
perspective has been taken into account during instru-
ment development. Systematic development of PRO
measures require qualitative research to identify key
concepts from patients’ perspectives, clinician input,
careful development of item content and response
scales, cognitive debriefing interviews, and the evaluation
of psychometric characteristics (i.e., reliability, validity,
responsiveness) [12]. In addition, the guidance from the
Food and Drug Administration (FDA) on the application
of PRO instruments for product labeling recommends val-
idation in the population of interest, including qualitative
research to elicit key concepts, cognitive interviewing, and
evaluation of psychometric properties [13].
Objective
The purpose of this three-tiered literature review was to
identify what concepts patients raise with regard to
CHC symptoms, disease impact, and treatment effects,
and to assess whether measurement of these concepts
have been integrated into PRO measures and clinical
trials. This was achieved through identification of con-
cepts, identification and review of PRO measures that
cover the key concepts that were identified, and
review of published clinical trial data to determine
what concepts are being measured in trials through
PRO measures and how PRO endpoints reflect clin-
ical changes.
Methods
A three-tiered literature review was conducted. This
included searches on concepts of importance to CHC
patients, PRO measures used in clinical trials, and exist-
ing PRO measures. The CHC PRO Concept Search was
designed to identify qualitative and quantitative research
reporting on the CHC patient experience to determine
concepts of importance to the CHC population. TheCHC Trials with PRO Endpoints Search was designed to
identify CHC clinical trials with PRO endpoints to deter-
mine whether PRO results show differentiation between
treatments over time. The PRO Measure Search was
designed to identify PRO measures that were either used
within CHC populations or contained domains that
mapped to the concepts of interest selected during the
CHC PRO Concept Search.
Inclusion and exclusion criteria
A priori inclusion and exclusion criteria were used to
guide identification and selection of literature and PRO
measures (see Table 1).
Databases
Literature searches were conducted in PubMed and
EMBASE databases. The CHC Trials with PRO End-
points Search also included review of CHC clinical
trials listed on the clinialtrials.gov website (1994–2009)
and the PRO Measure Search included review of the
Patient-Reported Outcome and Quality of Life Instru-
ments Database (PROQOLID). All sources are widely
used and accepted databases within the field of PRO
measurement.
Key search terms and screening process
Search terms for the CHC PRO Concept Search
included the following terms: CHC, HCV, hep C, hepa-
titis C, chronic hepatitis C, and methodological terms
such as qualitative, patient perspective, and focus group.
Abstracts identified through PubMed and EMBASE were
reviewed for eligibility, and eligibility was confirmed
when reviewing full-text articles. All CHC concepts
reported in the articles from the CHC PRO Concept
Search were recorded, and a list of the most common
concepts was generated.
Search terms for the CHC Trials with PRO Endpoints
Search included the CHC terminology used in the CHC
PRO Concept Search and terms for peginterferon alpha
2a and clinical trials. Additionally, when possible this
search was limited to clinical trial, controlled clinical
trial, randomized controlled trial, or Phase I-IV clinical
trials. Publications from relevant trials identified through
a search of clinicaltrial.gov were reviewed for eligibility,
and PRO measures were reviewed for inclusion in the
CHC Trials with PRO Endpoints Search and the PRO
Measure Search.
Results from the CHC PRO Concept Search and the
CHC Trials with PRO Endpoints Search guided the PRO
Measure Search, supplemented by findings from
PubMed, EMBASE, PROQOLID, and previous research
completed in CHC by the authors. From these multiple
sources, a pool of potential PRO measures was gener-
ated for consideration.
Table 1 Inclusion and exclusion criteria for the searches
CHC PRO concept search CHC trials with PRO endpoints search PRO measure search
Search Specific
Inclusion Criteria







research or article discussing
concepts relevant to CHC
disease or treatment.
• RCTs or non-randomized trials. • Reported on the development/
validation of a PRO instrument or one
of the concepts of interest selected
during the CHC PRO Concept Search.
• Patients in at least one arm must
have received pegylated interferon.
• Follow-up duration of at least 48 weeks. • PRO instrument designed for use in
CHC population or used in CHC
population; if no PROs available for a
particular concept of interest additional
methods were utilized.
• PRO data must have been reported
in a manner that allowed for determination
of differentiation between treatments over time.
CHC = Chronic Hepatitis C; RCT = Randomized controlled trials.
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Findings from PRO concept search
Seven-hundred and sixty-eight (768) abstracts were
reviewed during the PRO Concept Search. Ninety-two
(92) of these articles underwent full-text evaluation, with
74 articles found to be relevant to the search objectives
(Figure 1). These 74 articles included 31 review articles,
22 qualitative research articles that provided insight into
the CHC patient perspective, and 23 observational or
prospective study articles.
The PRO Concept Search identified 22 CHC-related con-
cepts mentioned in three or more articles (Figure 1). Con-
cepts included symptoms and treatment effects related to
mental health, physical health, pain, HRQL, activities of
daily living (ADL), cognitive dysfunction, and other categor-
ies. The most frequently reported CHC-related con-
cepts were: depression [5,6,10,14-30], fatigue [5,6,10,14-26],
anxiety/fear [5,6,10,14,17,18,21,22,25,27,28,30,31], mus-
culoskeletal pain/myalgia [6,10,16-18,20,22-24,26], flu-like
symptoms [6,10,17,18,23,24,26], irritability [6,16,18,23,29],
insomnia or sleep problems [5,6,10,15,18-20,23,24], loss
of appetite/anorexia/weight loss [6,10,17,20,23,24], social
functioning/isolation/stigma [5,6,10,14-19,22,26-30], gastro-
intestinal symptoms [5,6,10,17,18,20,24,26], reduced HRQL
[5,6,10,14,18,24,32], cognitive impairment [5,10,15,16,20,
23,24], and headache [10,18,20,22,24].
Twenty-two of the articles reported on qualitative stud-
ies of CHC patients that provided valuable insight into the
patient perspective [5,6,10,14-32]. The qualitative research
reviewed identified similar concepts as those listed above.
The most commonly reported symptoms were: fatigue
[5,6,10,14-26], depression [5,6,10,14-30], anxiety/fear,
and inability to function or social consequences of
disease [5,6,10,14,17,18,21,22,25,27,28,30]. Other outcomes,
including HCV symptoms and side effects of treatment,
were: cognitive dysfunction [5,10,15,16,20,23,24], musculo-
skeletal pain [6,10,16-18,20,22-24,26], gastrointestinal
symptoms [5,6,10,17,18,20,24,26], flu-like symptoms [6,10,17,18,23,24,26], dyspnea [18], headache [10,18,20,22,24],
reduced functional capacity [6,10,15,18,22,24], reduced
quality of life [5,6,10,14,18,24,32], insomnia or sleep pro-
blems [5,6,10,15,18-20,23,24], reduced sexual desire [24],
loss of appetite, weight loss or anorexia [6,10,17,20,23,24].
The qualitative research articles also demonstrated that
patients emphasized the impact of their CHC symptoms
and medication side effects on ADL and HRQL. The most
frequently mentioned impact was on social function
[5,6,10,14-19,22,26-31], including reduction in social activ-
ities, loss of social support, erosion of social roles, and
HCV-related stigma. Psychological consequences were
discussed along with a range of emotions, including grief
[17], guilt [6], frustration [21], shame [6,27], shock [17,22],
denial [6,22], despair [27], embarrassment [26], irritabi-
lity [6,16,18,23,29], and hostility or anger [6,10,15,17,
21-23,25,29]. Other emergent themes included difficulty at
work [5,6,10,15,18,24,26], uncertainty or a lack of know-
ledge about the virus [5,6,10,14,15,17,21,22,28,32], issues
related to stigma [5,6,14,15,19,22,27,29,30], and discussion
of treatment costs and benefits [6,10,14,18,19,21,23,25,
26,28,29,32].
The overall list of concepts was evaluated based on
ease of implementation into a clinical trial, potential
to detect change over time in a clinical trial, how fre-
quently the concepts appeared in the literature, how
often the concepts were a primary focus of an article,
and whether the concepts were independent or part
of a larger group of concepts. The following five con-
cepts were identified as being important to the CHC
patients, easily implemented in a clinical trial and
sensitive to change over time: 1) depression/anxiety;
2) fatigue; 3) flu-like symptoms; 4) cognitive function;
and 5) insomnia.
All of these concepts were endorsed by patients as
being bothersome symptoms or treatment effects related
to CHC in the qualitative research studies [5,6,10,14-30].
The concept of flu-like symptoms was considered to be
PRO Measure Search 
Identified 124 potential 
PRO measures through 
PROQOLID
PRO Measure Search 
Reviewed a total of 770 
abstracts mentioning PRO 
measures (PubMed, 
EMBASE)
PRO Measure Search 
Identified 67 potential 
PRO measures through 
the CHC PRO Concept 
Search
PRO Measure Search 
Identified 9 potential PRO 
measures through the 
CHC Trials with PRO 
Endpoints Search
Reviewed 187 PRO 
measures and associated 
literature
Selected 18 PRO 
measures for in-depth 
review
(see Table 3 for detail)
Reviewed 74 articles
Requested 92 articles
CHC PRO Concept Search
Reviewed 768 abstracts 






Irritability (n=23 total mentions) 
Insomnia or sleep problems (n=23)
Loss of appetite/anorexia/weight loss (n=23)
Social functioning/isolation/stigma (n=22)
Abdominal pain/nausea/vomiting/diarrhea (n=22)
Reduced health-related quality of life (n=19)
Cognitive dysfunction (n=18)
Headache (n=18)
Mental health -anger/hos tility/aggression (n=14)
Reduced functional capacity/physical and motor function (n=14)
Dermatological problems (n=14)
ADL and work impact, including loss of interest (n=14)
Mental health -mania/hypomania (n=7)
Dyspnea (n=7)
Mental health -psychosis/other  psychiatric disorders (n=6)
Weakness (n=6)
Sexual side effects (n=3)
Reviewed 7 articles
Requested 23 articles
CHC Trials with PRO Endpoints 
Search
Reviewed 392 abstracts 
(PubMed, EMBASE) and 265 clinical 
trials (clinical trials.gov)
Figure 1 Literature search results summary for the searches.
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that may be malleable to change especially as new ther-
apies are developed. The concepts of depression and
anxiety were combined because these concepts often
overlap and there are existing single measures that cover
both concepts (e.g., Hospital Anxiety and Depression
Scale); thus the concepts were combined.
PRO endpoint results from CHC trials
Three-hundred and ninety-two (392) abstracts were
identified through EMBASE and PubMed (Figure 1).
The clinicaltrials.gov search resulted in 265 clinical trials
(Figure 1). Twenty-nine (29) of these trials reported
including at least one PRO measure. After reviewing the
clinical trial abstracts, 23 articles were retrieved, and
seven of these publications met eligibility requirements
(see Tables 2 and 3) [3,33-36]. Five of these reported out-
comes based on the SF-36 Health Survey [3,33-36], andan additional trial reported outcomes based on the
Hepatitis Quality of Life Questionnaire (HQLQ), which
integrates the SF-36 with hepatitis-specific questions
[37]. Four utilized the Fatigue Severity Scale (FSS)
[3,33,34,36]. One trial each utilized the Work Productiv-
ity and Activity Impairment instrument (WPAI) [37], the
Hamilton Depression Rating Scale (HAM-D) [38] and,
the Zung Self-Rating Depression Scale (ZSRDS) [38]
(see Table 3). Overall, examination of the PRO measures
used in clinical trials for SOC for CHC demonstrated
inadequate coverage of the concepts discussed above.
Review of PRO measures
Eighteen PRO measures were selected for in-depth
review based on the findings of the three searches and
the a priori eligibility criteria (Table 1). Table 3 lists the
18 PRO measures by concept of interest. Instrument
characteristics such as the population in which the
Table 2 CHC Trials with PRO Endpoints Search - Clinical Trial Characteristics






CHC patients - SF-36 -HRQL Patients with an SVR had better SF-36 and
FSS scores than both virological non-
responders and patients in the untreated
control group at the end of follow-up (week
72; Table 2). In patients who received
combination therapy (groups A and B
combined), the differences in mean HRQL
scores between patients with an SVR and
virological non-responders were statistically
significant for five of eight SF-36 domains
(General Health, P < 0.0001; Bodily Pain
Index, P < 0.0001; Role Physical, P < 0.05;
Physical Functioning, P < 0.05; Vitality,
P < 0.0001) and the Physical Health
component score, P < 0.0001 (Table 2).
Consistent with these findings, both the FSS
Total score (P < 0.01 vs. non-responders)
and VAS score (P < 0.01 vs. non-responders)
were significantly better in patients with an
SVR.
N = 491 - FSS -Impact and severity of fatigue on HRQL
- Group A = 24 weeks; Prior therapy: Patients had not
received prior treatment for CHC.
Group B = 48 weeks;
No treatment = 72 weeks
-Pegylated interferon
alpha 2a + ribavarin
Bernstein
et al. [3]
- Open-label RCT CHC patients - SF-36 -Physical function, role limitations physical,
vitality, general health perceptions, pain,




- 72 weeks N = 676 - FSS 'Virologic response associated with positive




Prior therapy: none - Patients taking peginterferon reported
better HRQOL and less fatigue than
interferon in all FSS domains, and 7/8 of SF-
36 domains (exception Physical Function).
Hassanein
et al [34]
- Open-label RCT CHC patients - SF-36 -Physical function, role limitations physical,
vitality, general health perceptions, pain,
social function, role limitations-emotional,
mental health
(Results using ANCOVA)
- 72 weeks N = 1121 - FSS - Using the SF-36, the addition of ribavarin
to peginterferon increased HRQOL in
domains of physical function, role
limitations, vitality, social functioning, mental
health (not bodily pain, general health, role
limitations emotional).
-Peginterferon alfa-2a +placebo;
Peginterferon alfa-2a + ribavarin;
Interferon alfa2b + ribavarin
Prior therapy: None
- Using the FSS, the addition of ribavarin to
peginterferon increased HRQOL in domains
of total fatigue and fatigue severity.
-Fatigue
- Using the SF36, peginterferon (with
ribavarin) as compared to interferon (with
ribavarin) increased HRQOL in domains of
role limitations physical, bodily pain, vitality,
social functioning (not physical function,

























Table 2 CHC Trials with PRO Endpoints Search - Clinical Trial Characteristics (Continued)
- Using the FSS, peginterferon (with
ribavarin) as compared to interferon (with
ribavarin) increased HRQL in domains total




- Non-randomized trial CHC patients - SF-36 -Physical function, role limitations physical,
vitality, general health perceptions, pain,
social function, role limitations-emotional,
mental health
Use of the Mann Whitney U test revealed
no significant differences between the
treatment groups on any of the domains.N = 40- 72 weeks





- Randomized, open-label, prospective trial HCV patients - HAM-D Depression Logistic regression analysis showed in both
groups a significant trend from baseline
according to the ZSRDS (odds ratio 0.698,
p < 0.01 [95% CI 0.59, 0.78]) to predict early
major depressive disorders confirmed by the
study.
N = 186 - ZSRDS
Prior therapy: Not Reported- Follow-up once a month for 48 weeks of
treatment and 4 and 8 weeks after the end
of therapy
- SCID




- Open-label RCT CHC patients - HQLQ - HQLQ: social function, role limitations
emotional, vitality, general mental health,
physical function, role limitations physical,
freedom from pain, general health, health
distress, positive well-being, hepatitis-
specific limitations, hepatitis-specific health,
PCS, MCS.
ANCOVA was used to test differences in
change scores between treatment groups.
- 72 weeks N = 412 - WPAI
-Peginterferon alfa-2ª; Interferon alfa-2b +
ribavirin
Prior therapy: None - HRQL as measured on all domains
diminished during treatment for both
treatment groups.
- For all SF-36 scales, however, the
peginterferon alfa-2a group experienced less
impairment than did the interferon alfa-2 b
group.
- The between-treatment differences were
significant in 3 of the scales at week 48.
-WPAI: impact of therapies on work
productivity, health care utilization
Rasenack
et al. [36]
- Open-label, randomized, parallel-dose
study
CHC patients - FSS - HRQL -FSS- Statistically significant differences
between treatment groups favoring
peginterferon α-2a were seen in FSS total
scores at weeks 2, 12, and 24 and in FSS
VAS scores at weeks 2 and 12 (p < 0.01).
N = 531 - SF-36 - Fatigue
Prior therapy: None- 72 weeks
-SF-36- peginterferon α-2a patients
demonstrated significantly better mean
scores in all eight SF-36 domains (p < 0.01
to p < 0.05) compared with those treated
with unmodified interferon α-2a.
-Peginterferon α-2a (40kD); Unmodified
interferon α-2a
FSS - Fatigue Severity Scale; HAM-D - Hamilton Rating Scale for Depression; HQLQ - Hepatitis Quality of Life Questionnaire; SCID - structured clinical interview for DSM-IV disorders; SF-36 - Short-form Health Survey;




































FIS Flu-iiQ MOS-Cog ESS CLDQ1














Depression and anxiety: BDI - Beck Depression Inventory; BAI - Beck Anxiety
Inventory questionnaire; HADS - Hospital Anxiety and Depression Scale; CES-D
- Center for Epidemiologic Studies - Depression Scale; ZSRDS - Zung Self-Rated
Depression Scale; PROMIS - Patient Reported Outcome Measurement
Information System. Fatigue: FIS - Fatigue Impact Scale; FSS - Fatigue Severity
Scale; MAF - Multidimensional Assessment of Fatigue; PROMIS - Patient
Reported Outcome Measurement Information System. Flu-like symptoms: Flu-
iiQ - Symptom Intensity and Impact of Influenza Questionnaire; FIQ -
Fibromyalgia Impact Questionnaire. Note the Flu-iiQ was previously two
measures, the Influenza Symptom Severity scale (ISS) and the Influenza Impact
Wellbeing Scale (IIWS). The Flu-iiQ is a newer version of the measures that
encompasses both the ISS and IIWS. Cognitive Function: MOS-Cog - Medical
Outcomes Study Cognitive Scale; MOS-SS - Medical Outcomes Study Sleep
Scale. Insomnia: ESS - Epworth Sleepiness Scale; PSQI - Pittsburgh Sleep
Quality Index; PROMIS - Patient Reported Outcome Measurement Information
System Sleep Disturbance subscale. CHC specific measures: CLDQ - Chronic
Liver Disease Questionnaire; CLDQ-HCV - Chronic Liver Disease Questionnaire-
Hepatitis C Virus; HQLQ - Hepatitis Quality of Life Scale/Hepatitis Quality of Life
Questionnaire.
1 Four of the measures reviewed were validated in CHC populations, the FSS,
CLDQ, CLDQ-HCV, and HQLQ.
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instrument development, scale and scoring information,
recall period, and mode of administration were reviewed.
Four of the 18 PRO measures selected were validated in
CHC populations: Fatigue Severity Scale (FSS), the
Chronic Liver Disease Questionnaire (CLDQ), the
Chronic Liver Disease Questionnaire-Hepatitis C Virus
(CLDQ-HCV), the Hepatitis Quality of Life Question-
naire (HQLQ) [39,40]. Instrument development and psy-
chometric validation articles were examined for these
four PRO measures. Each of these measures has demon-
strated acceptable psychometric characteristics, including
internal consistency reliability [41,42], test-retest reliabil-
ity [41], construct validity [39-42], and known-groups
validity [39,41,42].
Conclusion and discussion
Chronic hepatitis C and its treatment are associated with
a wide variety of symptoms and impacts as reported by
patients. We examined a variety of published CHCstudies in order to identify concepts that capture the
patient experience of CHC and have the potential to be
sensitive to change due to treatment. Based on these
considerations, five concepts of interest were selected
for further investigation within publications of clinical
trials with CHC patients that included PRO measure-
ment and publications of PRO development and psycho-
metric evaluation studies. These five concepts were
selected based on their perceived sensitivity to change in
disease status, either by progression or treatment, and
sensitive to treatment effects. Our goal was to determine
if the concepts we identified through the literature as
providing insight into the perspective of CHC patients
had been translated into PRO instruments, and whether
the published clinical trials reported PRO data that
reflect clinical changes, ideally within the concepts that
were identified as important to CHC patients.
Examination of the PRO measures used in clinical
trials for SOC for CHC demonstrated inadequate cover-
age of the concepts of: 1) depression/anxiety; 2) fatigue;
3) flu-like symptoms; 4) cognitive function; and 5) insomnia.
Instruments measuring HRQL were frequently included
in clinical trials. Clinical trials also sometimes included
measures of fatigue, depression, and anxiety, but were
less likely to include measures of cognitive function, in-
somnia, and flu-like symptoms. Incorporating PRO
measures of the concepts of interest that have been
validated for use within CHC populations into clinical
trials would provide additional useful information on
compliance and treatment maintenance. Further,
instruments are available to measure almost all of the
top five concepts identified as being important to
patients; that is, depression/anxiety, fatigue, flu-like
symptoms, cognitive function, and insomnia.
Qualitative studies evaluating the content validity of
PRO measures are important to verify whether or not
the instrument is measuring concepts that are relevant
and important to patients. Only one of the 18 instru-
ments reviewed, the HQLQ, had evidence demonstrating
content validity in the CHC population. The FSS and
CLDQ, both psychometrically validated in the CHC
population, included qualitative interviews with patients
as part of the PRO development process, but the qualita-
tive research was not specifically conducted in the CHC
population.
Recommendations for measuring the concept
of depression/anxiety
The Hospital Anxiety and Depression Scale (HADS)
may be a potential PRO instrument for use in measuring
anxiety and depression in CHC studies. The advantages
of the HADS is that it is a single, short questionnaire
and has been used in prior clinical trials of CHC as well
as with many other physical illnesses to measure the
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HADS is a well-validated measure in other disease areas;
however, it is lacking any type of content validity or psy-
chometric evidence in a CHC sample. Qualitative
research is recommended to assess whether the HADS
anxiety and depression items cover relevant aspects of
the CHC experience and to ensure that CHC patients
understand the items, response scales, and instructions.
In addition, studies aimed at evaluating the reliability
and validity of the HADS within the CHC population
are needed.
Recommendations for measuring the concept of fatigue
The Fatigue Severity Scale (FSS) may be a useful PRO
measure for assessing fatigue-related symptoms in CHC.
The FSS covers fatigue-related symptoms and impact of
fatigue on functioning. The FSS has been used in several
prior trials comparing treatments for CHC and has been
demonstrated to be responsive to change over time and
predictive of treatment discontinuation. Additionally, it
is a short questionnaire, which may result in little bur-
den on patients. The FSS has demonstrated excellent
psychometric characteristics in the CHC [41]. Qualita-
tive research on the FSS within CHC populations is
needed to determine if the FSS item content is consist-
ent with the patient experience in CHC.
Recommendations for measuring the concept of flu-like
symptoms
Several instruments are available to measure influenza
symptoms; however, not all symptoms of influenza are
relevant to the general malaise often felt by patients with
CHC. Symptoms such as nasal congestion, sore throat,
and cough are more unique to influenza and would not
be appropriate for use in CHC. Future qualitative
research is needed to identify which flu-like symptoms
are most salient and relevant to patients with CHC. The
goal of this research would be to develop a daily diary or
PRO measure that can be used to assess the most com-
mon flu-like symptoms.
Recommendations for measuring the concept of cognitive
function
There are many existing neuropsychological tests and
batteries that are available to measure all aspects of cog-
nitive function. Administration of neuropsychological
tests and batteries requires training for individuals who
will administer the test, which can be time-consuming
and have cost implications. Further neuropsychological
tests may not accurately reflect patients’ complaints and
may not be able to measure impairment levels that are
relevant for CHC. One alternative to neuropsychological
tests and batteries may be to utilize a PRO measure,
such as the Medical Outcomes Study – Cognitive Scale(MOS-Cog), to assess cognition [43,44]. This measure
contains six items that cover reasoning, concentration
and thinking, confusion, memory, attention, and psycho-
motor function. Currently, the MOS-Cog is not vali-
dated in CHC populations; however, it was used in
general primary care surveys, such as the Medical Out-
comes Study [44]. Qualitative and quantitative research
is needed before the MOS-Cog can be confidently used
in CHC studies.
Recommendations for utilizing item banks
There are also recently developed measures of depres-
sion, anxiety, fatigue, and sleep disturbance, based on
item banks, from the National Institutes of Health PRO-
MIS project [45-48], that have the potential to improve
measurement of these PRO domains. Item banks enable
intelligent design of short-form scales where items are
selected to best assess the construct based on knowledge
about the patient’s health status. In addition, these item
banks allow for computer adaptive testing, which
involves tailoring the measure to individual patients.
Computer adaptive tests are individualized and can be
set for specific levels of measurement precision (i.e., reli-
ability) at the individual level. These types of applica-
tions and methods may represent the future of health
outcomes assessment.
Limitations
Several limitations should be considered related to this
review. First, this review only focused on a limited num-
ber of CHC-related concepts. These concepts, although
relevant to patients with CHC, do not encompass all the
PRO domains relevant to CHC. This was primarily
because of our focus on providing recommendations for
PRO measures to be used in CHC clinical trials. Second,
we limited the review to SOC clinical trials to identify
instruments measuring the previously identified con-
cepts. Therefore, some PRO concepts included in earlier
clinical trials may have been missed. Finally, we did not
examine available PRO instruments developed using a
mixed population of patients with a variety of liver dis-
eases [49-51] but focused solely on PROs developed with
patient populations that were solely CHC or PRO mea-
sures developed for concepts identified that were of
interest to CHC patients. Instruments developed using
mixed patient populations pooled the results and did
not report solely on the CHC patients.
Summary
In summary, this review identified gaps in the PRO
measurement literature regarding assessment of symp-
toms and outcomes that are reported to be important by
patients with CHC. Further research is needed to ensure
that the measures used in CHC clinical trials are
Kleinman et al. Health and Quality of Life Outcomes 2012, 10:92 Page 9 of 10
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CHC patients and have evidence supporting content val-
idity, reliability, construct validity, and responsiveness.
Some qualitative research has been completed in CHC
patients, and the information from these studies can
then be used to develop new measures to assess relevant
PRO domains. Clearly, PROs are necessary for assessing
the impact of CHC and treatment for CHC from the
patient’s perspective, and these PRO endpoints are im-
portant to include in CHC clinical trials.
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